
Teclistamab Combo Yields Deep Responses in Newly Diagnosed Myeloma
The MajesTEC-5 trial (NCT05695508), a phase 2 study evaluating teclistamab-cqyv (Tecvayli) combined with standard myeloma therapies in patients with transplant-eligible newly diagnosed multiple myeloma, demonstrated promising safety and efficacy, with 100% …